Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Pramlintide: they're closely matched on evidence (4.5 vs 5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Empagliflozin and Pramlintide are closely matched across evidence, studies, and safety.
Verdict
Helped
7 of 7 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Empagliflozin and Pramlintide have evidence — compare verdict strength side-by-side.
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Morning
Oral tablet (empagliflozin)
Prescription-only, clinician-titrated. Subcutaneous injection immediately before major meals. Type 1 diabetes: typically start 15 µg and titrate to 30-60 µg per meal. Type 2 diabetes (on mealtime insulin): typically start 60 µg and titrate to 120 µg per meal. Reduce mealtime insulin (often by ~50%) when starting. DO NOT self-dose.
With meals
Subcutaneous pre-meal injection (Symlin / SymlinPen)
and 1 more not shown
Weeks
Months to years
Months to years
Weeks to months
Weeks to 6-12 months
Per meal / weeks
Months
The label describes severe hypoglycaemia, when it occurs, within three hours after a Symlin injection; this is not a guarantee of no risk at other times.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · RCT · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · RCT
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · RCT
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Diabet Med (2004) · RCT · n=651
Double-blind, placebo-controlled, parallel-group multicentre trial in 651 patients with type 1 diabetes, mealtime pramlintide at varying doses or placebo added to insulin for 52 weeks.
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Diabetes Care (2002) · RCT · n=480
52-week double-blind, placebo-controlled trial in 480 patients with type 1 diabetes, pramlintide 30 µg four times daily or placebo added to insulin. At week 20, pramlintide patients whose HbA1c had fallen less than 1% by week 13 were re-randomised to 30 or 60 µg.
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Diabetes Care (2003) · RCT · n=656
52-week double-blind, placebo-controlled, parallel-group multicentre trial in 656 insulin-treated patients with type 2 diabetes, randomised to placebo or pramlintide 60 µg three times daily, 90 µg twice daily or 120 µg twice daily.
Both Empagliflozin and Pramlintide are closely matched — the best choice depends on your specific health goals.
For manage blood sugar, Empagliflozin has a higher relevance score (62 vs 56).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.